Yes it is a good article. I followed McCamant's years ago when he was high on IMGN, the other biotech stock I have a big position in. He's quite knowledgeable, and perhaps he was right in getting out of IMGN when he did, but I suspect he'll be back in with both feet shortly.
GNVC's potential is tremendous, but it's pipeline outside of TNFerade is largely being ignored. I believe when the pipeline gains credibility, in addition to positive TNFerade data, this stock should go even higher than the article indicated.
While it would be nice to see a partner on one or more of the company's drugs, I only want to see it if the company's satisfied with the price. GNVC can operate without such a partnership well into the clinical approval process, the longer they take a drug through trials the more it's worth, provided it works. If an interested potential partner is unwilling to pay GNVC's price now, they may find they're willing to pay a much higher price when more trial data's available. As long as the data looks good the closer the drug is to approval, the higher the price will be.
Gary |
